Quantum Cyber N.V.

The company, which intends to change its name to Quantum Cyber N.V. and currently uses Quantum Cyber as a d/b/a, is headquartered in Mainz, Germany, and had approximately 10 full-time and 3 part-time employees as of March 30, 2026. Historically, the company developed and sold in-vitro diagnostic (IVD) tests for the early detection of cancer. In March 2025, it acquired an exclusive license from Liquid Bioscience, Inc. for a portfolio of novel mRNA biomarkers and an AI-developed proprietary algorithm for the non-invasive detection of pancreatic cancer using a blood test, with a unilateral option to acquire them. The company is also developing PancAlert, a stool-based screening test for pancreatic cancer, which has received non-refundable government grant income covering a percentage of its project-related costs. In its 2025 fiscal year, the company marketed and sold its ColoAlert product in European markets and developed a next-generation colorectal cancer screening product. However, in February 2026, the board decided to wind down ColoAlert and the development of next-generation colorectal cancer screening product candidates. On March 28, 2026, the intellectual property for ColoAlert was sold, and the intellectual property for the next-generation colorectal cancer screening product candidates is actively being marketed for sale. In February and March 2026, new board appointments were made to align the company's strategy to expand its business focus into post-quantum cybersecurity, while continuing to commercialize its blood-based pancreatic cancer detection product candidate. The company's Nasdaq ticker symbol was changed to "QUCY".